Tigecycline: An overview and update

Therapy

Volumn 6, Issue 6, 2009, Pages 851-870

  Blondeau, Joseph M ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Broad spectrum; Multidrug resistant; Overview; Tigecycline; Update

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CILASTATIN PLUS IMIPENEM; DIGOXIN; LEVOFLOXACIN; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHARMACOLOGICAL BLOCKING; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 70449640864     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.74     Document Type: Review

References (119)

1. Peterson LR: Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline (symposium section). Diagn. Microbiol. Infect. Dis. 52, 163-164 (2005).
2. Livermore DM: Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56, 611-614 (2005).
3. Kim A, Kuti JL, Nicolau DP: Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin. Investig. Drugs 16(5), 717-733 (2007). (Pubitemid 46723274)
4. Moellering RC Jr: Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138, 135-142 (2003).
5. Kern WV: Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int. J. Clin. Pract. 60(3), 370-378 (2006).
6. Food and Drug Administration: Determination that tequin (gatifloxacin) was withdrawn from sale for reasons of safety or effectiveness. Federal Register, ed., Docket No. FDA-2004-N-0451, Health and Human Services, 73(1755), 52357-52358 (2008).
7. Chopra I: Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1, 464-469 (2001).
8. Zhanel GG, Homenuik K, Nichol KA et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs 64(1), 63-88 (2004).
9. Guay DRP: Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 24, 58-68 (2004).
10. Pankey GA: Tigecycline. J. Antimicrob. Chemother. 56, 470-480 (2005).
11. Rubinstein E, Vaughan D: Tigecycline: a novel glycylcycline. Drugs 65(10), 1317-1336 (2005).
12. Chopra I, Roberts MC: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232-260 (2001). (Pubitemid 32538179)
13. 2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53, 592-599 (2004).
14. Projan SJ: Preclinical pharmacology of gar936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20(9 Pt 2), S219-S223 (2000).
15. Pioletti M, Schluenzen F, Harms J et al.: Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20(8), 1829-1839 (2001).
16. + antiporter. Antimicrob. Agents Chemother. 39(1), 247-249 (1995).
17. Sum PE, Sum FW, Projan SJ: Recent developments in tetracycline antibiotics. Curr. Pharm. Des. 4, 119-132 (1998).
18. Chopra I: New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updat. 5, 119-125 (2002).
19. Blondeau JM, Borsos S: The killing of E. coli by tigecycline using the minimum inhibitory and mutant prevention drug concentration. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, March 31-April 3 2007.
20. Doan T-L, Fung HB, Mehta D, Riska PF: Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther. 28(8), 1079-1106 (2006).
21. Muralidharan G, Micalizzi M, Speth J et al.: Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrobil 49, 220-229 (2005). (Pubitemid 40065796)
22. Conte JE Jr, Golden J, Kelly MG, Zurlinden E: Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25, 523-529 (2005). (Pubitemid 40732607)
23. Sun HK, Ong CT, Umer A et al.: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49, 1629-1632 (2005). (Pubitemid 40463407)
24. 14C) tigecycline in human volunteers following intravenous infusion. AAPS J. 6(Suppl. 1) (2006) (Abstract W5301).
25. Van Wart SA, Cirincione BB, Ludwig EA et al.: Population pharmacokinetics of tigecycline in healthy volunteers. J. Clin. Pharmacol. 47, 727-737 (2007).
26. Macgowan A: Tigecycline pharmacokinetic/pharmacodynamic update. J. Antimicrob. Chemother. 62(Suppl. 1), I11-I16 (2008).
27. Tygacil® package insert. Wyeth Pharmaceuticals, NJ, USA (2006).
28. Zimmerman JJ, Harper D, Matschke K et al.: Tigecycline and digoxin co-administered to healthy men. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, December 16-19 (2004).
29. Fraise AP: Tigecycline: The answer to blactam and fluoroquinolone resistance? J. Infect. 53, 293-300 (2006).
30. Schafer JJ, Goff DA, Stevenson KB, Mangino JE: Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27(7), 980-987 (2007).
31. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ: Tigecycline for treatment of pneumonia and empyema caused by carbapenemaseproducing Klebsiella pneumoniae. Pharmacotherapy 27(7), 1052-1057 (2007).
32. Anthony KB, Fishman NO, Linkin DR et al.: Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 587-1570 (2008).
33. Giamarellou H, Poulakou G: Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69(14), 1879-1901 (2009).
34. Scheetz MH, Qi C, Warren JR et al.: In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(5), 1621-1626 (2007). (Pubitemid 46744136)
35. Sands M, Mccarter Y, Sanchez W: Synergy testing of multidrug resistant Acinetobacter baumannii against tigecycline and polymyxin using an e-test methodology. Eur. J. Clin. Microbiol. Infect. Dis. 26(7), 521-522 (2007). (Pubitemid 47025046)
36. Arroyo LA, Mateos I, Gonzalez V et al.: In vitro activities of tigecycline, minocycline and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob. Agents Chemother. 53(3), 1295-1296 (2009).
37. Dong Y, Zhao X, Domagala J, Drlica K: Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 1756-1758 (1999). (Pubitemid 29331261)
38. Firsch AW, Tripp JT, Barrett CD Jr, Pidgeon BE: Specific polysaccaride content of pneumoni lungs. J. Exp. Med. 76, 505-510 (1942).
39. Bingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P et al.: Bacterial counts in cerebrospinal fluid of children with meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 9, 278-281. (1990). (Pubitemid 20157330)
40. Fagon J, Chastre J, Trouillet JL et al.: Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 142(5), 1004-1008 (1990). (Pubitemid 20384350)
41. Feldman W: Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J. Pediatr. 88, 549-552 (1976).
42. Low DE: Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin. Infect. Dis. 33(Suppl. 3), S206-S213 (2001).
43. Blondeau J, Zhao X, Hansen GT, Drlica K: Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001). (Pubitemid 32105277)
44. Metzler KL, Borsos S, Hansen G, Blondeau JM: Determination of the mutant prevention concentration (MPC) for several antimicrobial agents (AA) against clinical isolates of Staphylococcus aureus (SA). Presented at: Canadian Microbiology Association. Saskatoon, SK, Canada, June (2002).
45. Hansen G, Zhao X, Drlica K, Blondeau JM: Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 27, 120-124 (2006).
46. Hansen G, Blondeau JM: Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 17(5), 484-492 (2005). (Pubitemid 41695595)
47. Hedlin P, Blondeau JM: Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae. Eye Contact Lens 33(3), 161-164 (2007). (Pubitemid 46763367)
48. Hesje C, Tillotson GS, Blondeau JM: MICS, MPCS and PK/PDS: a match (sometimes) made in hosts. Expert Rev. Respir. Med. 1(1), 7-16 (2007).
49. Blondeau J: What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J. Antimicrob. Chemother. 63(2), 238-242 (2008).
50. Blondeau J, Hesje C, Borsos S: Mutant prevention concentration (MPC) values for tigecycline (TIG) tested against E. coli isolates collected in 2007. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, October 25-28 (2008).
51. Blondeau JM, Borsos S, Hesje C: Determination of the minimum inhibitory and mutant prevention concentration of tigecycline against clinical isolates of E. coli and Klebsiella species. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, March 31-April 3 (2007).
52. Blondeau J, Hesje C, Borsos S: Tigecycline (TIG) has a low propensity to select for resistant Streptococcus pneumoniae (SP) by mutant prevention concentration (MPC) testing. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, October 25-28 (2008).
53. Blondeau JM, Hesje C, Borsos S: Determination of the minimum inhibitory concentration and mutant prevention concentration of tigecycline against clinical isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, March 31-April 3 (2007).
54. Hesje C, Borsos S, Blondeau J: Determination of the minimum inhibitory concentration and mutant prevention concentration of tigecycline against clinical isolates of methicillin-resistant Staphylococcus aureus: impact of bloond on susceptibility results. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, April 19-22 (2008).
55. Blondeau JM, Barks B, Borsos S, Sanche SE: Mutant prevention concentration of tigecycline and vancomycin against contemporary clinical isolates of Clostridium difficile. Presented at: 19th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID). Helsinki, Finland, May 16-19 (2009).
56. Deery HG: Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect. Dis. Clin. North Am. 12, 935-949 (1998).
57. Nichols RL, Florman S: Clinical presentations of soft-tissue infections and surgical site infections. Clin. Infect. Dis. 33(Suppl. 2), S84-S93 (2001).
58. Nichols RL: Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44, 19-23 (1999).
59. Postier RG, Green SL, Klein SR et al.: Results of a multicenter, randomized, peon-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26, 704-714 (2004).
60. Sacchidanand S, Penn RL, Embil JM et al.: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin-structure infections: results from a Phase 3, randomized, double-blind trial. Int. J. Infect. Dis. 9, 251-261 (2005). (Pubitemid 41196869)
61. Breedt J, Teras J, Gardovskis J et al.: Safety and efficacy of tigecycline ind treatment of skin and skin-structure infections: results of a double-blind Phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 49, 4658-4666 (2005). (Pubitemid 41552597)
62. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose GM, Loh E: The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341-S353 (2005). (Pubitemid 41170381)
63. Solomkin JS, Mazuski JE, Baron EJ et al.: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37, 997-1005 (2003).
64. Gorbach S: Intraabdominal infections. Clin. Infect. Dis. 17, 961-965 (1993).
65. Lorber B, Swenson RM: The bacteriology of intra-abdominal infections. Surg. Clin. North Am. 55, 1349-1354 (1975).
66. Burnett R, Haverstock DC, Dellinger EP et al.: Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 118, 716-721 (1995).
67. Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit. Care Med. 31, 2228-2237 (2003).
68. Krobot K, Yin D, Zhang Q et al.: Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired infections requiring surgery. Eur. J. Clin. Microbiol. Infect. Dis. 23, 683-687 (2004). (Pubitemid 39304322)
69. Oliva ME, Rekha A, Yellin A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infectious Diseases 5, 88. (2005).
70. Murray JJ, Wilson SE, Klein SR, Yellin A, Loh E: The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase 2 clinical trial. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, September 14-17 (2003).
71. Babinchak T, Ellis-Grosse EJ, Dartois N, Rose GM, Loh E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5), S354-S367 (2005). (Pubitemid 41170382)
72. Blondeau J, Borsos S: Comparative mutant prevention concentration values for tigecycline and ciprofloxacin against clinical isolates of Escherichia coli. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, April 19-22 (2008).
73. Hesje C, Borsos S, Blondeau JM: Determination of the minimum inhibitory concentration and mutant prevention concentration (MPC) of tigecycline against clinical isolates of Streptococcus pneumoniae: impact of media on MPC results. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Munich, Germany, March 31-April 3 (2007).
74. Mandell LA, Wunderink RG, Anzueto A et al.: Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007). (Pubitemid 46290553)
75. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37(11), 1405-1433 (2003).
76. Tanaseanu C, Bergallo C, Teglia O et al.: Integrated results of 2 Phase 3 studies comparing tigecycline and levofloxacin in communityacquired pneumonia. Diagn. Microbiol. Infect. Dis. 61, 329-338 (2008). (Pubitemid 351858575)
77. Bergallo C, Jasovich A, Teglia O et al.: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized Phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 63, 52-61 (2009).
78. Blondeau JM: What have we learned about antimicrobial use and the risks of Clostridium difficile-associated diarrhoea? J. Antimicrob. Chemother. 63(2), 238-242 (2009).
79. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr: Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16, 459-477 (1995).
80. Al-Tureihi FI, Hassoun A, Wolf-Klein L, Isenberg HD: Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J. Am. Med. Dir. Assoc. 6, 105-108 (2005). (Pubitemid 40353089)
81. Bignardi GE: Risk factors for Clostridium difficile infection. J. Hosp. Infect. 40, 1-15 (1998).
82. Sharma P, Bomireddy R, Phillips S: Clostridium difficile-associated diarrhoea after internal fixation of intertrochanteric femoral fractures. Eur. J. Clin. Microbiol. Infect. Dis. 22, 615-618 (2003). (Pubitemid 37363542)
83. Patel NS: Fluoroquinolone use is the predominant risk factor for the development of a new strain of Clostridium difficile-associated disease. BJU Int. 99(6), 1333-1334 (2007).
84. Wilcox MH: Evidence of low risk of Clostridium difficile infection associated with tigecycline. Clin. Microbiol. Infect. 13, 949-952 (2007).
85. Settle CD, Wilcox MH, Fawley WN et al.: Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin/tazobactam. Aliment. Pharmacol. Ther. 12, 1217-1223 (1998).
86. Wilcox MH, Freeman J, Fawley WN et al.: Longterm surveillance of cefotaxime and piperacillin/tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 54, 168-172 (2004). (Pubitemid 39028985)
87. Herpers BL, Vlaminckx B, Burkhardt O et al.: Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 48, 1732-1735 (2009).
88. Nord CE, Sillerstrom E, Wahlund E: Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob. Agents Chemother. 50, 375-380 (2006).
89. Townsend ML: Tigecycline: a new glycylcycline antimicrobial. Int. J. Clin. Pract. 60(12), 1662-1672 (2006).
90. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52, 203-208 (2005).
91. Sader HS, Jones RN, Stilwell MG et al.: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52, 181-186 (2005).
92. Fritsche TR, Sader HS, Stilwell MG et al.: Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52, 195-201 (2005).
93. Fritsche TR, Sader HS, Stilwell MG et al.: Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52, 187-193 (2005).
94. Fritsche TR, Strabala PA, Sader HS et al.: Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis. 52, 209-213 (2005).
95. Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of gar936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 40, 173-177 (2001).
96. Fritsche TR, Kirby JT, Jones RN: In vitro activity of tigecycline (gar-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn. Microbiol. Infect. Dis. 49, 201-209 (2004).
97. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ: In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (test program, 2004). Diagn. Microbiol. Infect. Dis. 52, 215-227 (2005).
98. Bouchillon SK, Hoban DJ, Johnson B et al.: In vitro activity of tigecycline against 3938 Gram-negative and Gram-positive clinical isolates from the United States: Tigecycline evaluation and surveillance trial (test program, 2004). Diagn. Microbiol. Infect. Dis. 52, 173-179 (2005). (Pubitemid 41133542)
99. Betriu C, Rodriguez Avial I, Sanchez BA et al.: In vitro activities of tigecycline (gar936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46, 892-895 (2002). (Pubitemid 34157684)
100. Boucher HW, Wennersten CB, Eliopoulos GM: In vitro activities of the glycylcycline gar-936 against Gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2225-2229 (2000).
101. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma hominis, M. Pneumoniae and Ureaplasma urealyticum to gar936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared with their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45, 2604-2608 (2001).
102. Roblin PM, Hammerschlag MR: In vitro activity of gar-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents 20, 61-63 (2000).
103. Gales AC, Jones RN: Antimicrobial activity and spectrum of the new glycylcycline, gar-936, tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36, 19-36 (2000).
104. Bouchillon SK, Hoban DJ, Johnson B et al.: In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51, 291-295 (2005).
105. Bradford PA, Weaver-Sands DT, Petersen PJ: In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5), S315-S332 (2005).
106. Jacobus NV, Mcdermott LA, Ruthazer R, Snydman DR: In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48, 1034-1036 (2004). (Pubitemid 38280363)
107. Goldstein EJ, Citron DM, Merriam CV et al.: Comparative in vitro activities of gar-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 44, 2747-2751 (2000).
108. Edlund C, Nord CE: In vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcycline. Clin. Microbiol. Infect. 6, 159-163 (2000). (Pubitemid 34960211)
109. Bouchillon SK, Stevens T, Johnson JH et al.: Methicillin-resistant Staphylococcus aureus (1030) collected from a recent global population: tigecycline in vitro evaluation. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, October 30-November 2 (2005).
110. Laplante KL, Rybak MJ: Clinical glycopeptideinter-mediate staphylococci tested against arbekacin, daptomycin and tigecycline. Diagn. Microbiol. Infect. Dis. 50, 125-130 (2004).
111. Tenover FC, Weigel LM, Appelbaum PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48, 275-280 (2004).
112. Bozdogan B, Esel D, Whitener C et al.: Antibacterial susceptibility of a vancomycin-resistant Staphylococus aureus strain isolated at the Hershey medical center. J. Antimicrob. Chemother. 52, 864-868 (2003). (Pubitemid 37407819)
113. Fritsche TR, Jones RN: Antimicrobial activity of tigecycline (gar936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob. Agents 24, 567-571 (2004).
114. Johnson B, Bouchillon SK, Stevens T et al.: Vancomycin-resistant enterococci (VRE): a global problem: evaluation of tigecycline against recent isolates from multicenters globally. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, October 30-November 2 (2005).
115. Johnson B, Bouchillon SK, Stevens T et al.: Determining tigecycline's in vitro activity against multi-drug resistant Enterobacteriaceae from the test program - global data. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, October 30-November 2 (2005).
116. Betriu C, Gomez M, Rodriguez I et al.: In vitro activity of tigecycline and comparative antimicrobial agents against ampicillin-resistant Haemophilus influenzae isolates. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, December 16-19 (2004).
117. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, Loh E: Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal infections. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, December 16-19 (2004).
118. Blondeau J: Stat: Steps to antimicrobial therapy: A guide to management of infectious diseases. North American Compendiums Inc., MI, USA and ON, Canada (2008).
119. US Food and Drug Administration: FDA public health advisory: Ketek® (telithromycin) tablets (2006) www.fda.gov/Cder/Drug/advisory/telithromycin.htm (Last modified February 16, 2007)